PFNX - COVID-19 Collaboration For Johnson & Johnson's Janssen Unit And Other News: The Good Bad And Ugly Of Biopharma
Janssen Signs Collaboration with ImmunoPrecise Antibodies
Johnson & Johnson (JNJ) reported that its biotech unit Janssen Research & Development has signed a new deal with ImmunoPrecise Antibodies Ltd. (IPATF). The new deal offers Janssen an exclusive access to an array of novel and monoclonal antibodies against an undisclosed target. The company will also have an option to acquire all commercial rights to such antibodies. However, the companies did not disclose the financial terms and conditions of the collaboration.
ImmunoPrecise has entered into the deal through its subsidiary Talem Therapeutics, which is